Plain-English translation of NCT06995898 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
The Vanguard Study is testing two new blood tests—called Shield and Avantect—that may be able to detect cancer before symptoms appear. Researchers want to see if these tests are practical to use and whether they can find cancer at earlier, more treatable stages. You would be part of a large study enrolling 24,000 people to help answer these important questions.
Most cancers are easier to treat when found early. Current screening methods work well for some cancers but not others. This study exists to see if blood tests can offer a simpler, less invasive way to screen for multiple types of cancer at once.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn at your first visit and again one year later. Depending on which group you are randomly assigned to, you may receive results from the new blood tests or serve as a comparison group. If you receive test results showing possible cancer, you will follow up with your doctor for additional testing. The study will also ask you to complete questionnaires and allow access to your medical records to track outcomes over time.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States